Study of a Pembrolizumab-based Organ Preservation Strategy for Locally Advanced Larynx Cancers — SMART-KEY

Squamous Cell Carcinoma of Larynx Clinical Trial

Official title:
A Single-arm, Multi-institutional, Phase 2 Study of a Pembrolizumab-based Organ Preservation Strategy for Locally Advanced Larynx Cancers

Status Active, not recruiting

Clinical Trial Summary

This a prospective, single-arm, multi-institutional, open label, phase 2 trial evaluating the effects of induction chemo-immunotherapy, followed by radioimmunotherapy, followed by consolidation immunotherapy in patients with locally advanced squamous cell carcinoma of the larynx who are candidates for organ preservation.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Laryngeal Diseases
Laryngeal Neoplasms
Squamous Cell Carcinoma of Head and Neck
Squamous Cell Carcinoma of Larynx

Clinical Trial Details

NCT number	NCT04943445
Study type	Interventional
Source	Latin American Cooperative Oncology Group
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	February 22, 2022
Completion date	December 2024

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT06137378` - European Larynx Organ Preservation Study (ELOS) [MK-3475-C44]	Phase 2
Completed	`NCT02035735` - Interest of Narrow Band Imaging in Detection of Upper Aerodigestive Cancers	N/A
Recruiting	`NCT05144698` - RAPA-201 Therapy of Solid Tumors	Phase 1/Phase 2